Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 104.17B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.39 |
| PE Ratio | 16.40 |
| Forward PE | 10.39 |
| Dividend | 3.92 (4.60%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 1,733,455 |
| Average Volume | 1,685,036 |
| Open | 85.59 |
| Previous Close | 85.23 |
| Day's Range | 84.87 - 85.78 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.37 |
| RSI | 49.86 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Novavax Completes Marketing Authorization Transfers For Nuvaxovid To Sanofi
(RTTNews) - Novavax (NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), enabling Sanofi to take full responsibility for commercia...
Sanofi extends agreement with Medidata on clinical trials
Medidata And Sanofi Expand Collaboration To Advance Clinical Research Innovation
(RTTNews) - Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry, announced an extension of its strategic partnership with Sanofi. Unde...
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care Expanded 10-plus-year collaboration will levera...
Sanofi Breaks Above 200-Day Moving Average - Bullish for SNY
In trading on Friday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $51.00, changing hands as high as $52.20 per share. Sanofi shares are currently trading up about 4.7%...
Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launches
Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launches
Sanofi: Is Dupixent Too Successful?
Q3 2025 Sanofi SA Earnings Call Transcript
Q3 2025 Sanofi SA Earnings Call Transcript
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Sanofi 2025 Q3 - Results - Earnings Call Presentation
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
Sanofi SA (NASDAQ: SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion . Sales increased 2.3% year over year, up 7% in constant currency...
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Sanofi (SNY) Surpasses Q3 2025 Expectations Driven by Dupixent Sales
Sanofi (SNY) Surpasses Q3 2025 Expectations Driven by Dupixent Sales
Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion
Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent.
Sanofi's â¬4 Billion Drug Ignites Rally--But the Clock Is Ticking
Sanofi's â¬4 Billion Drug Ignites Rally--But the Clock Is Ticking
Sanofi (SNY) Projects Solid Growth in 2025
Sanofi (SNY) Projects Solid Growth in 2025
Sanofi (SNY) Reports Strong Third Quarter Amid Strategic Initiatives
Sanofi (SNY) Reports Strong Third Quarter Amid Strategic Initiatives
Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent
Earnings Scheduled For October 24, 2025
Companies Reporting Before The Bell • Eni (NYSE: E) is expected to report quarterly earnings at $0.73 per share on revenue of $22.45 billion. • NatWest Group (NYSE: NWG) is estimated to report earni...
Sanofi (SNY) Boosts Q3 Profits Through Strategic Pharma Launches
Sanofi (SNY) Boosts Q3 Profits Through Strategic Pharma Launches
Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance
Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.
Sanofi Q3 Profit Edges Down, Net Sales Rise; Confirms FY25 View, Sees Profitable Growth In FY26
(RTTNews) - French drug major Sanofi (SNY) reported Friday slightly lower profit in its third quarter, even as net sales were higher, benefited mainly by strong growth in Dupixent, which for the first...